2031년까지 세계 및 필리핀 암 치료제 시장 전망

Global & Philippines Cancer Therapeutics Market to 2031

상품코드Peru Cancer Therapeutics Market.pdf
발행기관Business Market Insights
발행일2025.05.26
페이지 수100 Pages
포맷PDF
커버리지Country

₩3,600,000 – ₩6,600,000

보고서 요약(국문)

필리핀의 암 치료제 시장은 표적 치료, 면역 치료, 생물학적 제제 등 혁신적인 치료법 도입에 힘입어 수요가 증가하고 있습니다. 특히 국가 통합 암 관리법(National Integrated Cancer Control Act)과 필리핀 건강보험공사(PhilHealth)를 통한 정부의 노력은 암 치료 서비스 및 의약품 접근성 향상에 크게 기여했습니다. 그러나 이러한 발전에도 불구하고, 높은 치료 비용과 국가 의료 인프라의 한계는 여전히 시장 확대를 저해하는 요인으로 작용하고 있습니다.

필리핀에서 암은 여전히 ​​주요 질병 및 사망 원인이며, 필리핀 암 협회(Philippine Cancer Society)에 따르면 매년 20만 건 이상의 새로운 암 진단 사례가 발생하고 있습니다. 이러한 증가하는 부담에 대응하여 화학 요법, 면역 요법, 표적 치료, 생물학적 제제를 포함한 항암제 시장은 빠르게 성장하고 있습니다. 더욱 개인 맞춤형이고 발전된 치료법으로의 전환은 필리핀의 암 관리 방식을 혁신적으로 변화시키고 있습니다.

국가통합암관리법과 더불어 필헬스(PhilHealth)는 암 치료 서비스를 의료보험 혜택에 포함시켜 환자들의 재정적 부담을 완화하는 데 중요한 역할을 해왔습니다. 특정 암 진단을 받은 환자들은 화학요법, 방사선 치료, 수술 등의 시술에 대해 부분적인 환급을 받을 수 있습니다. 필헬스의 암 치료제 프로그램은 특히 의료비 본인 부담이 여전히 만연한 의료 시스템에서, 재정적 장벽에 직면할 수 있는 사람들이 필수적인 치료를 더 쉽게 받을 수 있도록 해 주었습니다.

보고서 요약(영어 원문)

The cancer therapeutics market in the Philippines is witnessing growing demand, driven by the introduction of innovative treatments such as targeted therapies, immunotherapies, and biologics. Government efforts, notably through the National Integrated Cancer Control Act and the Philippine Health Insurance Corporation (PhilHealth), have significantly contributed to enhancing access to cancer care services and medications. Despite these advancements, challenges persist—particularly the high cost of therapies and limitations within the country’s healthcare infrastructure—which continue to restrict broader market expansion.

Cancer remains a leading cause of illness and death in the Philippines, with the Philippine Cancer Society reporting over 200,000 new diagnoses annually. In response to this growing burden, the oncology drug market—including chemotherapy, immunotherapy, targeted treatments, and biologics—has seen rapid growth. This transition toward more personalized and advanced therapies is transforming the way cancer is managed in the country.

Alongside the National Integrated Cancer Control Act, PhilHealth has been instrumental in easing the financial burden on patients by incorporating cancer treatment services into its benefit packages. Patients diagnosed with certain cancers can receive partial reimbursements for procedures such as chemotherapy, radiation, and surgery. PhilHealth’s cancer drug program has made vital treatments more accessible to individuals who may otherwise face significant financial barriers, especially in a healthcare system where out-of-pocket expenses are still widespread.

상세 목차

TABLE OF CONTENTS

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation:

4. Philippines Cancer Therapeutics Market Landscape

4.1 Overview

4.2 Ecosystem Analysis

4.2.1 List of Vendors in the Value Chain

5. Cancer Therapeutics Market Key Market Dynamics

5.1 Cancer Therapeutics Market – Key Market Dynamics

5.2 Market Drivers

5.3 Market Restraints

5.4 Market Opportunities

5.5 Future Trends

5.6 Impact of Drivers and Restraints

6. Philippines Cancer Therapeutics Market – Analysis

6.1 Philippines Cancer Therapeutics Market Revenue (US$ Million), 2021–2031

6.2 Philippines Cancer Therapeutics Market Revenue and Forecast Analysis

7. Philippines Cancer Therapeutics Market Analysis – by Therapy Types

7.1 Philippines Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types

8. Philippines Cancer Therapeutics Market Analysis – by Indications

8.1 Philippines Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications

9. Philippines Cancer Therapeutics Market Analysis – by Distribution Channel

9.1 Philippines Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel

10. Competitive Landscape

10.1 Heat Map Analysis by Key Players

10.1 Company Positioning and Concentration

11. Industry Landscape

11.1 Overview

11.2 Market Initiative

11.2 Partnerships and Collaborations

11.2 Other Developments

12. Company Profiles

12.1 Bristol-Myers Squibb Co

12.1. 1 Key Facts

12.1. 2 Business Description

12.1. 3 Products and Services

12.1. 4 Financial Overview

12.1. 5 SWOT Analysis

12.1. 6 Key Developments

12.2 AbbVie Inc

12.2. 1 Key Facts

12.2. 2 Business Description

12.2. 3 Products and Services

12.2. 4 Financial Overview

12.2. 5 SWOT Analysis

12.2. 6 Key Developments

12.3 Johnson & Johnson

12.3. 1 Key Facts

12.3. 2 Business Description

12.3. 3 Products and Services

12.3. 4 Financial Overview

12.3. 5 SWOT Analysis

12.3. 6 Key Developments

12.4 F. Hoffmann-La Roche Ltd

12.4. 1 Key Facts

12.4. 2 Business Description

12.4. 3 Products and Services

12.4. 4 Financial Overview

12.4. 5 SWOT Analysis

12.4. 6 Key Developments

12.5 Pfizer Inc

12.5. 1 Key Facts

12.5. 2 Business Description

12.5. 3 Products and Services

12.5. 4 Financial Overview

12.5. 5 SWOT Analysis

12.5. 6 Key Developments

12.6 AstraZeneca Plc

12.6. 1 Key Facts

12.6. 2 Business Description

12.6. 3 Products and Services

12.6. 4 Financial Overview

12.6. 5 SWOT Analysis

12.6. 6 Key Developments

12.7 Merck KGaA

12.7. 1 Key Facts

12.7. 2 Business Description

12.7. 3 Products and Services

12.7. 4 Financial Overview

12.7. 5 SWOT Analysis

12.7. 6 Key Developments

12.8 Novartis AG

12.8. 1 Key Facts

12.8. 2 Business Description

12.8. 3 Products and Services

12.8. 4 Financial Overview

12.8. 5 SWOT Analysis

12.8. 6 Key Developments

12.9 Astellas Pharma Inc

12.9. 1 Key Facts

12.9. 2 Business Description

12.9. 3 Products and Services

12.9. 4 Financial Overview

12.9. 5 SWOT Analysis

12.9. 6 Key Developments

12.10 Eli Lilly and Co

12.10. 1 Key Facts

12.10. 2 Business Description

12.10. 3 Products and Services

12.10. 4 Financial Overview

12.10. 5 SWOT Analysis

12.10. 6 Key Developments

13. Appendix

13.1 About Business Market Insights

13.2 List of Abbreviations

언급된 주요 기업들

TABLE OF COMPANIES

1. Bristol-Myers Squibb Co

2. AbbVie Inc

3. Johnson & Johnson

4. F. Hoffmann-La Roche Ltd

5. Pfizer Inc

6. AstraZeneca Plc

7. Merck KGaA

8. Novartis AG

9. Astellas Pharma Inc

10. Eli Lilly and Co

표 목록 (Tables)

TABLE OF TABLES

Table 1. Philippines Cancer Therapeutics Market Segmentation

Table 2. List of Vendors

Table 3. Philippines Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million)

Table 4. Philippines Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million)

Table 5. Philippines Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Therapy Types

Table 6. Philippines Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Therapy Types

Table 7. Philippines Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Indications

Table 8. Philippines Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Indications

Table 9. Philippines Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel

Table 10. Philippines Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel

Table 11. List of Abbreviations

그림 목록 (Figures)

TABLE OF FIGURES

Figure 1. Impact Analysis of Drivers and Restraints

Figure 2. Philippines Cancer Therapeutics Market Revenue, (US$ Million), 2021–2031

Figure 3. Heat Map Analysis by Key Players

Figure 4. Company Positioning and Concentration